A critical and often overlooked factor in managing hyperglycemia is hydration. Volume depletion from drug-induced diarrhea impairs the kidneys' ability to excrete glucose. This traps sugar in the body, creating a vicious cycle that dramatically elevates blood glucose levels.

While known for weight loss, GLP-1 agonists are also highly effective for managing hyperglycemia from both steroids and PI3K inhibitors. Using low or "micro" doses can be very helpful in cancer patients, providing glucose control while minimizing GI side effects like nausea.

Advances in drug design mean newer PI3K inhibitors are more targeted, resulting in significantly less off-target toxicity. For example, some investigational agents have a hyperglycemia risk under 15%, a substantial improvement over earlier drugs, making them easier to manage clinically.

Clinicians are hesitant to use insulin for PI3K inhibitor-induced hyperglycemia. The primary concern is that exogenous insulin, a potent growth factor, could theoretically counteract the therapy's anti-tumor effect by promoting cancer cell survival, although this risk remains unproven.

A patient with normal baseline glucose on an AKT inhibitor can experience a sudden, severe spike in blood sugar when they get sick (e.g., fever, infection). The illness acts as a physiological stressor, creating a "perfect storm" that demands immediate attention and patient education.

Second-generation PI3K inhibitor enovalisib has a 7% discontinuation rate compared to 25% for its predecessor, alpelisib. This is due to a better toxicity profile (e.g., 6% vs. 33% high-grade hyperglycemia) and improved proactive side effect management by clinicians.

Oncologists typically initiate metformin for drug-induced hyperglycemia but are hesitant to manage more complex regimens. They prefer collaborating with endocrinologists who can navigate different drugs, dosages, and interactions, especially for complex oncology patients where frequent follow-up is needed.

A patient's diabetes must be well-managed before starting the inavolisib triplet, with an HbA1c below 8. The pivotal trial used an even stricter cutoff of 6.0. Proactive management, including consideration of continuous glucose monitoring, is critical to prevent severe hyperglycemia, a major toxicity of this effective regimen.

Testing for PI3K/AKT alterations at the initial diagnosis of metastatic disease, rather than waiting for progression, provides a crucial window of time. This allows clinicians to implement proactive dietary and medical strategies to mitigate future side effects like hyperglycemia before the targeted therapy is even started.